Black Diamond Therapeutics (BDTX) Common Equity (2018 - 2026)

Black Diamond Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $104.3 million for Q1 2026.

• Quarterly Common Equity fell 26.3% year-over-year to $104.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.3 million (down 26.3% YoY) and the FY2025 annual result came in at $112.2 million, up 34.73% from the prior year.
• Common Equity was $104.3 million for Q1 2026 at Black Diamond Therapeutics, down from $112.2 million in the prior quarter.
• Across five years, Common Equity topped out at $172.6 million in Q1 2022 and bottomed at $82.2 million in Q2 2023.
• A 5-year average of $118.7 million and a median of $115.7 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity tumbled 46.05% — and 2025, when it soared 35.67%.
• Black Diamond Therapeutics' Common Equity stood at $115.7 million in 2022, then grew by 0.9% to $116.7 million in 2023, then decreased by 28.66% to $83.3 million in 2024, then jumped by 34.73% to $112.2 million in 2025, then decreased by 7.05% to $104.3 million in 2026.
• Business Quant data shows BDTX's Common Equity at $104.3 million in Q1 2026, $112.2 million in Q4 2025, and $126.2 million in Q3 2025.